Gan & Lee Pharmaceuticals announced the appointment of Dr. John Wang as Senior Vice President and Chief Strategy Officer, effective January 12, 2026. Dr. Wang will oversee the company's business development and strategic collaborations, spearheading Gan & Lee's global expansion and portfolio diversification across multiple therapeutic areas. Dr. Wang brings over 30 years of distinguished experience in the pharmaceutical industry, spanning R&D, corporate strategy, and commercialization.
He possesses a proven track record in business development, including in-licensing, out-licensing, and alliance management. His expertise covers the entire lifecycle of strategic growth?from early-stage project evaluation and due diligence to cross-functional execution and global implementation. Dr. Wang holds a Ph.D. in Pharmacology from the University of London and conducted postdoctoral research at Harvard University and Boston University School of Medicine.
His career began at Wyeth Pharmaceuticals, initially focusing on R&D in neuroscience and CVMD fields. He subsequently transitioned to business development and strategic partnerships, holding leadership roles at global pharmaceutical leaders including Sanofi, Merck, Eli Lilly, and Simcere Pharmaceutical Group. Over the course of his career, Dr. Wang has led or facilitated strategic collaborations and investments with a cumulative value exceeding USD 10 billion, demonstrating exceptional capabilities in resource integration and strategic execution.
